Co-Diagnostics, Inc.
CODX
Rank in Stocks
#31904
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops,... Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Share Price
$0.319
Last synced: 2026-11-09
Market Cap
$2.38M
Change (1 day)
24.22%
Change (1 year)
-97.31%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Co-Diagnostics, Inc. (CODX)
Category
Healthcare
Number of shares outstanding for Co-Diagnostics, Inc. (CODX)
Number of shares outstanding as of June 2026: 4.31M
According to Co-Diagnostics, Inc.'s latest financial reports, its current number of shares outstanding is 4.31M. At the end of 2025 the company had 1.33M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Co-Diagnostics, Inc. (CODX) from 2014 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 4.31M | 224.01% |
| 2025 | 1.33M | 31.55% |
| 2024 | 1.01M | 3.37% |
| 2023 | 978.22K | -6.77% |
| 2022 | 1.05M | 9.02% |
| 2021 | 962.49K | 8.06% |
| 2020 | 890.67K | 59.46% |
| 2019 | 558.56K | 34.22% |
| 2018 | 416.15K | 13.91% |
| 2017 | 365.34K | -0.91% |
| 2016 | 368.70K | 0.00% |
| 2015 | 368.70K | 40.81% |
| 2014 | 261.84K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 5,781.67% |
US
|
|
| 401.00M | 9,203.95% |
US
|
|
| 478.91M | 11,011.65% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | 1,355.58% |
NL
|
Questions about Co-Diagnostics, Inc.'s number of shares outstanding
What is Co-Diagnostics, Inc.'s number of shares outstanding?
Co-Diagnostics, Inc.'s number of shares outstanding is 4.31M, as of Jun 2026.
What was Co-Diagnostics, Inc.'s number of shares outstanding in 2025?
In 2025, Co-Diagnostics, Inc.'s number of shares outstanding was 1.33M, 31.55% more than in 2024 (1.01M).
How has Co-Diagnostics, Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, Co-Diagnostics, Inc.'s number of shares outstanding went from 890.67K to 1.33M, an average growth of 8.35% a year.